US Government As Represented by the Secretary of the Army

Alnylam Pharmaceuticals, Inc.

Avi Biopharma, Inc.

U.S. Army Medical Research and Material Command

The United States of America, As Represented by the Secretary, Department of Health and Human Services

The United States of America As Represented by the Army

The United States of America As Represented by the Army Medical Research and Material Command

Sarepta Therapeutics, Inc.

U.S. Army Medical Research Institute of Infectious Diseases Department of the Army

United States Government As Represented by the Secretary of the United States Army and the U.S. Army Medical Research & Materiel Command

Sina Bavari

Kelly Lyn Warfield

Antonin De Fougerolles

Pamela Tan

Tatiana Novobrantseva

Anna Borodovsky

Patrick L Iversen

David A Stein

Mark A Olson

Dwight D Weller

Robert G Ulrich

Rick Gussio

James C Burnett

Frank J Lebeda

Edna R Torres Melendez

Rekha G Panchal

Mohammad Javad Aman

Alan L Schmaljohn

James J Schmidt

Tam Nguyen

Steven Bradfute

Krishnamurthy Konduru

Gerardo Kaplan

Robert G Ulrích

Jonathan E Nuss

Jerome Jacques

Ann Hermone

M Javad Aman

Dana Swenson

This invention provides fusion proteins comprising a Filovirus glycoprotein segment and an immunoglobulin polypeptide segment. The fusion proteins are useful in immunogenic compositions to protect against infections by Filoviruses, such as Ebola virus, in both humans and non-human animals. The fusion proteins are also useful in diagnostic assays to detect Filovirus infections.

Fusion protein comprising the extracellular domain of a filovirus glycoprotein fused to an immunoglobulin heavy chain constant region

The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of a gene from the Ebola virus.

Compositions and methods for inhibiting expression of a gene from the Ebola virus

We disclose cleavage-sensitive antibodies with epitopes spanning the scissile bond of the toxins molecular target protein, enabling toxin-associated proteolysis to be measured in a variety of assay formats.

Cleavage sensitive antibodies and methods of use thereof

The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of the CD45 gene.

Compositions and methods for inhibiting expression of CD45 gene

The present invention relates to genetically attenuated superantigen toxin vaccines altered such that superantigen attributes are absent, however the superantigen is effectively recognized and an appropriate immune response is produced. The attenuated superantigen toxins are shown to protect animals against challenge with wild type toxin. Methods of producing and using the altered superantigen toxins are described.

Bacterial superantigen vaccines

Disclosed herein are methods of inhibiting, reducing or preventing growth of or destroying bacteria of at least one bacterial strain which comprises contacting the bacteria with the compounds disclosed herein. Also disclosed are methods of treating, inhibiting or preventing an infection or intoxication caused by bacteria of at least one bacterial strain in a subject and pharmaceutical and cosmetic compositions comprising the compounds disclosed herein.

Broad spectrum antibacterial compounds

Compositions and methods for inhibiting expression of a gene from the ebola virus

The invention provides antisense antiviral compounds and methods of their use and production in inhibition of growth of viruses of the Filoviridae family, and in the treatment of a viral infection. The compounds and methods relate to the treatment of viral infections in mammals including primates by Ebola and Marburg viruses. The antisense antiviral compounds are morpholino oligonucleotides having: a) a nuclease resistant backbone, b) 15-40 nucleotide bases, and c) a targeting sequence of at least 15 bases in length that hybridizes to a target region selected from the following: i) the Ebola virus AUG start site region of VP24; ii) the Ebola virus AUG start site region of VP35; iii) the Marburg virus AUG start site region of VP24; or iv) the Marburg virus AUG start site region of NP.

Antisense antiviral compounds and methods for treating a filovirus infection

Disclosed herein are compounds which exhibit antiviral activity against a plurality of viruses belonging to different families such as Bornaviridae, Filoviridae, Paramyxoviridae, Rhabdoviridae, Arenaviridae, Bunyaviridae, Orthomyxoviridae, and Poxviridae. Thus, methods of preventing, inhibiting, or reducing the viral activity of various viruses are provided as well as methods of treating viral infections.

Antiviral compounds and methods of using thereof

Growing community of inventors

Frederick, MD, United States of America

Sina Bavari